VCRE
VCRE clinical trials: Vicore Pharma Holding AB
Every trial on ClinicalTrials.gov where Vicore Pharma Holding AB is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VCRE on the catalyst calendar · VCRE registry changes
- Primary completion May 2027Sponsor estimatePhase 2NCT06588686A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.Vicore Pharma AB · Idiopathic Pulmonary Fibrosis (IPF)Active, not recruitingVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2024ActualPhase 2NCT04533022Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFVicore Pharma AB · Idiopathic Pulmonary FibrosisCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2022ActualPhase 1NCT05277922Effect of C21 on Forearm Blood FlowVicore Pharma AB · Study Vasodilatory Effects of C21CompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2023ActualPhase 1NCT05427253First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy SubjectsVicore Pharma AB · Safety IssuesCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2023ActualPhase 1NCT05830799A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy VolunteersVicore Pharma AB · Drug InteractionCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2023ActualPhase 1NCT05831644A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 DiabetesVicore Pharma AB · Type2diabetesCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2023ActualNo phase registeredNCT05330312Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PFVicore Pharma AB · Pulmonary FibrosisCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2021ActualNo phase registeredNCT04878913Retrospective Evaluation of Lung Pathology in Subjects With COVID-19Vicore Pharma AB · COVID-19CompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2022ActualPhase 3NCT04880642A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsVicore Pharma AB · COVID-19CompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2020ActualPhase 2NCT04388176Cold Challenge With C21 in RPVicore Pharma AB · Raynaud PhenomenonCompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2020ActualPhase 2NCT04452435Safety and Efficacy of C21 in Subjects With COVID-19Vicore Pharma AB · COVID-19CompletedVCRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner